Mesoporous silicon: a platform for the delivery of therapeutics

Prestidge, Clive A.; Barnes, Timothy J.; Lau, Chi-Hian; Barnett, Christian; Loni, A.; Canham, Leigh

doi:10.1517/17425247.4.2.101

Cited by 123 publications

(101 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Porous silicon has been under pre-clinical evaluation for drug delivery for a number of years [1][2][3][4][5][6]. Its medical biodegradability and biocompatibility [7][8][9], widely tuneable pore sizes via electrochemical etching [10,11], flexible surface chemistry [12,13] and high payloads of nanostructured drugs [14] are its key attributes in this regard.…”

Section: Introductionmentioning

confidence: 99%

Quantification and Reduction of the Residual Chemical Reactivity of Passivated Biodegradable Porous Silicon for Drug Delivery Applications

Shabir¹,

Webb²,

Nadarassan³

et al. 2017

Silicon

View full text Add to dashboard Cite

The chemical reactivity of as-anodized porous silicon is shown to have an adverse effect on a model drug (Lansoprazole) loaded into the pores. The silicon hydride surfaces can cause unwanted reactions with actives during storage or use. Techniques such as thermal oxidation or surface derivatization can lower the reactivity somewhat, by replacing the reactive silicon-hydride species with a more benign oxide or functional group. However, by using a trio of analytical techniques (fluorometric dye assay, HPLC assay, and chemography) we show that residual hydride is still likely to be present and only after combining thermal oxidation with surface derivatization can the residual reactivity be reduced to those values typically observed with sol-gel (porous) silica. Potential sources of residual reactivity are discussed, with reference to data obtained by trace metal analysis, residual solvents, and pH measurements.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantification and Reduction of the Residual Chemical Reactivity of Passivated Biodegradable Porous Silicon for Drug Delivery Applications

Shabir¹,

Webb²,

Nadarassan³

et al. 2017

Silicon

View full text Add to dashboard Cite

show abstract

“…By careful fine-tuning the porous silicon carrier properties it is possible 3 to attain zero order drug release kinetics and develop novel pharmaceutical devices such as insulin pumps [14,15] and gastrointestinal patches for oral insulin delivery [16,17]. Some recent studies have studied protein loading into porous silicon layers [18][19][20][21], and there is a general consensus that this is a complex process that can be influenced by the morphology of the silicon device, its nanostructure, and the device surface chemistry [22]. However a systematic approach would improve our understanding of the physicochemical processes involved in protein-porous silicon interaction, and ultimately, it would lead to optimized formulations for protein delivery.…”

Section: Introductionmentioning

confidence: 99%

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Pastor

Matveeva

Valle-Gallego

et al. 2011

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

Mesoporous silicon is a biocompatible, biodegradable material that is receiving increased attention for pharmaceutical applications due to its extensive specific surface. This feature enables to load a variety of drugs in mesoporous silicon devices by simple adsorption-based procedures. In this work, we have addressed the fabrication and characterization of two new mesoporous silicon devices prepared by electrochemistry and intended for protein delivery, namely: (i) mesoporous silicon microparticles and (ii) chitosan-coated mesoporous silicon microparticles. Both carriers were investigated for their capacity to load a therapeutic protein (insulin) and a model antigen (bovine serum albumin) by adsorption. Our results show that mesoporous silicon microparticles prepared by electrochemical methods present moderate affinity for insulin and high affinity for albumin. However, mesoporous silicon presents an extensive capacity to load both proteins, leading to systems were protein could represent the major mass fraction of the formulation. The possibility to form a chitosan coating on the microparticles surface was confirmed both qualitatively by atomic force microscopy and quantitatively by a colorimetric method.Mesoporous silicon microparticles with mean pore size of 35 nm released the loaded insulin quickly, but not instantaneously. This profile could be slowed to a certain extent by the chitosan coating modification. With their high protein loading, their capacity to provide a controlled release of insulin over a period of 60-90 min, and the potential mucoadhesive effect of the chitosan coating, these composite devices comprise several features that render them interesting candidates as transmucosal protein delivery systems.

show abstract

“…4,13 Hence implanted devices will eventually degrade away and not require surgical removal. It is the degradation that sees PSi used as a material for drug delivery of poorly solubilised drugs.…”

Section: (L)mentioning

confidence: 99%

“…4,5 Hence PSi also has potential to be applied in theranostics. Mesoporous silicon, where pores are in the size range of 2-50 nm, is the most relevant material for these applications.…”

Section: Introductionmentioning

confidence: 99%

“…Tuning the optical signature to the near-IR between 700-1000 nm is particularly attractive as transmission through tissue is then possible 10 and hence PSi may be amenable to implantable devices for non-invasive interrogation. Another aspect of PSi that makes it attractive for use in biological systems, such as in vivo applications, is that PSi has been shown to degrade in aqueous solution to orthosilicic acid by the following mechanisms: 11 Si(s) + 2H 2 O(l) / SiO 2 (s) + 2H 2 (g) SiO 2 (s) + 2H 2 O(l) / Si(OH) 4 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mesoporous silicon photonic crystal microparticles: towards single-cell optical biosensors

et al. 2011

View full text Add to dashboard Cite

In this paper we demonstrate the possibility of modifying porous silicon (PSi) particles with surface chemistry and recognition molecules (antibodies) such that these devices could potentially be used for singlecell identification or sensing. This is achieved by modifying PSi Rugate filters via hydrosilylation with surface chemistry that serves firstly, to protect the silicon surfaces from oxidation; secondly, renders the surfaces resistant to nonspecific adsorption of proteins and cells and thirdly, allows further functionality to be added such as the coupling of antibodies. The surface chemistry remained unchanged after sonication of the PSi to form PSi microparticles. The ability to monitor the spectroscopic properties of microparticles, and shifts in the optical signature due to changes in the refractive index of the material within the pore space, is demonstrated. The particles are shown to remain stable in physiological buffers and human blood for longer than one week. Finally, the modification of the PSi particles with functional antibodies is achieved.

show abstract

Mesoporous silicon: a platform for the delivery of therapeutics

Cited by 123 publications

References 45 publications

Quantification and Reduction of the Residual Chemical Reactivity of Passivated Biodegradable Porous Silicon for Drug Delivery Applications

Quantification and Reduction of the Residual Chemical Reactivity of Passivated Biodegradable Porous Silicon for Drug Delivery Applications

Protein delivery based on uncoated and chitosan-coated mesoporous silicon microparticles

Mesoporous silicon photonic crystal microparticles: towards single-cell optical biosensors

Contact Info

Product

Resources

About